A snapshot of biologic drug development: Challenges and opportunities
Since the approval of insulin as the first recombinant therapeutic protein, the prominence of biologic therapies in drug development has grown significantly. Many modalities beyond traditional biologics are now being developed or explored for various indications with significant unmet medical needs....
Gespeichert in:
| Veröffentlicht in: | Human & experimental toxicology 2015-12, Vol.34 (12), p.1279-1285 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1285 |
|---|---|
| container_issue | 12 |
| container_start_page | 1279 |
| container_title | Human & experimental toxicology |
| container_volume | 34 |
| creator | Andrews, L Ralston, S Blomme, E Barnhart, K |
| description | Since the approval of insulin as the first recombinant therapeutic protein, the prominence of biologic therapies in drug development has grown significantly. Many modalities beyond traditional biologics are now being developed or explored for various indications with significant unmet medical needs. From early traditional replacement proteins to more recent, highly engineered antibodies, oligonucleotides, fusion proteins, and gene constructs, biologic agents have delivered life-changing therapies, despite often having scientifically and technically challenging development programs. This brief review outlines some of the major biotherapeutic classes and identifies the advantages and challenges with the development of these products. |
| doi_str_mv | 10.1177/0960327115603594 |
| format | Article |
| fullrecord | <record><control><sourceid>sage_AFRWT</sourceid><recordid>TN_cdi_crossref_primary_10_1177_0960327115603594</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0960327115603594</sage_id><sourcerecordid>10.1177_0960327115603594</sourcerecordid><originalsourceid>FETCH-LOGICAL-c290t-73d545102af7dff6320d9b693d881b36a906a79251e5a4dbe324d7d775705c433</originalsourceid><addsrcrecordid>eNp1jz1LxEAURQdR3HW1t5J0VtH35jNTLourwoKN1mGSmcQsSSZkEsF_b0LUQrC6xb3nwiHkGuEOUal70BIYVYhiSqH5CVkjVyoGDeyUrOc6nvsVuQjhCABSCzwnKyol8gTlmtxuo9CaLrz7IfJFlFW-9mWVR7Yfy8i6D1f7rnHtcEnOClMHd_WdG_K2f3jdPcWHl8fn3fYQ51TDECtmBRcI1BTKFoVkFKzOpGY2STBj0miQRmkq0AnDbeYY5VZZpYQCkXPGNgSW37z3IfSuSLu-akz_mSKks3P613lCbhakG7PG2V_gR3IaxMsgmNKlRz_27aTw_-EXSBhcGw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A snapshot of biologic drug development: Challenges and opportunities</title><source>Sage Journals GOLD Open Access 2024</source><creator>Andrews, L ; Ralston, S ; Blomme, E ; Barnhart, K</creator><creatorcontrib>Andrews, L ; Ralston, S ; Blomme, E ; Barnhart, K</creatorcontrib><description>Since the approval of insulin as the first recombinant therapeutic protein, the prominence of biologic therapies in drug development has grown significantly. Many modalities beyond traditional biologics are now being developed or explored for various indications with significant unmet medical needs. From early traditional replacement proteins to more recent, highly engineered antibodies, oligonucleotides, fusion proteins, and gene constructs, biologic agents have delivered life-changing therapies, despite often having scientifically and technically challenging development programs. This brief review outlines some of the major biotherapeutic classes and identifies the advantages and challenges with the development of these products.</description><identifier>ISSN: 0960-3271</identifier><identifier>EISSN: 1477-0903</identifier><identifier>DOI: 10.1177/0960327115603594</identifier><identifier>PMID: 26614816</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Animals ; Antibodies, Monoclonal - therapeutic use ; Biological Products - therapeutic use ; Genetic Therapy ; Humans ; Nucleic Acids - therapeutic use</subject><ispartof>Human & experimental toxicology, 2015-12, Vol.34 (12), p.1279-1285</ispartof><rights>The Author(s) 2015</rights><rights>The Author(s) 2015.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c290t-73d545102af7dff6320d9b693d881b36a906a79251e5a4dbe324d7d775705c433</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0960327115603594$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0960327115603594$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21965,27852,27923,27924,44944,45332</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.1177/0960327115603594?utm_source=summon&utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26614816$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Andrews, L</creatorcontrib><creatorcontrib>Ralston, S</creatorcontrib><creatorcontrib>Blomme, E</creatorcontrib><creatorcontrib>Barnhart, K</creatorcontrib><title>A snapshot of biologic drug development: Challenges and opportunities</title><title>Human & experimental toxicology</title><addtitle>Hum Exp Toxicol</addtitle><description>Since the approval of insulin as the first recombinant therapeutic protein, the prominence of biologic therapies in drug development has grown significantly. Many modalities beyond traditional biologics are now being developed or explored for various indications with significant unmet medical needs. From early traditional replacement proteins to more recent, highly engineered antibodies, oligonucleotides, fusion proteins, and gene constructs, biologic agents have delivered life-changing therapies, despite often having scientifically and technically challenging development programs. This brief review outlines some of the major biotherapeutic classes and identifies the advantages and challenges with the development of these products.</description><subject>Animals</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Biological Products - therapeutic use</subject><subject>Genetic Therapy</subject><subject>Humans</subject><subject>Nucleic Acids - therapeutic use</subject><issn>0960-3271</issn><issn>1477-0903</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1jz1LxEAURQdR3HW1t5J0VtH35jNTLourwoKN1mGSmcQsSSZkEsF_b0LUQrC6xb3nwiHkGuEOUal70BIYVYhiSqH5CVkjVyoGDeyUrOc6nvsVuQjhCABSCzwnKyol8gTlmtxuo9CaLrz7IfJFlFW-9mWVR7Yfy8i6D1f7rnHtcEnOClMHd_WdG_K2f3jdPcWHl8fn3fYQ51TDECtmBRcI1BTKFoVkFKzOpGY2STBj0miQRmkq0AnDbeYY5VZZpYQCkXPGNgSW37z3IfSuSLu-akz_mSKks3P613lCbhakG7PG2V_gR3IaxMsgmNKlRz_27aTw_-EXSBhcGw</recordid><startdate>201512</startdate><enddate>201512</enddate><creator>Andrews, L</creator><creator>Ralston, S</creator><creator>Blomme, E</creator><creator>Barnhart, K</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201512</creationdate><title>A snapshot of biologic drug development</title><author>Andrews, L ; Ralston, S ; Blomme, E ; Barnhart, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c290t-73d545102af7dff6320d9b693d881b36a906a79251e5a4dbe324d7d775705c433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Biological Products - therapeutic use</topic><topic>Genetic Therapy</topic><topic>Humans</topic><topic>Nucleic Acids - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Andrews, L</creatorcontrib><creatorcontrib>Ralston, S</creatorcontrib><creatorcontrib>Blomme, E</creatorcontrib><creatorcontrib>Barnhart, K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Human & experimental toxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Andrews, L</au><au>Ralston, S</au><au>Blomme, E</au><au>Barnhart, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A snapshot of biologic drug development: Challenges and opportunities</atitle><jtitle>Human & experimental toxicology</jtitle><addtitle>Hum Exp Toxicol</addtitle><date>2015-12</date><risdate>2015</risdate><volume>34</volume><issue>12</issue><spage>1279</spage><epage>1285</epage><pages>1279-1285</pages><issn>0960-3271</issn><eissn>1477-0903</eissn><abstract>Since the approval of insulin as the first recombinant therapeutic protein, the prominence of biologic therapies in drug development has grown significantly. Many modalities beyond traditional biologics are now being developed or explored for various indications with significant unmet medical needs. From early traditional replacement proteins to more recent, highly engineered antibodies, oligonucleotides, fusion proteins, and gene constructs, biologic agents have delivered life-changing therapies, despite often having scientifically and technically challenging development programs. This brief review outlines some of the major biotherapeutic classes and identifies the advantages and challenges with the development of these products.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>26614816</pmid><doi>10.1177/0960327115603594</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 0960-3271 |
| ispartof | Human & experimental toxicology, 2015-12, Vol.34 (12), p.1279-1285 |
| issn | 0960-3271 1477-0903 |
| language | eng |
| recordid | cdi_crossref_primary_10_1177_0960327115603594 |
| source | Sage Journals GOLD Open Access 2024 |
| subjects | Animals Antibodies, Monoclonal - therapeutic use Biological Products - therapeutic use Genetic Therapy Humans Nucleic Acids - therapeutic use |
| title | A snapshot of biologic drug development: Challenges and opportunities |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T19%3A16%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sage_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20snapshot%20of%20biologic%20drug%20development:%20Challenges%20and%20opportunities&rft.jtitle=Human%20&%20experimental%20toxicology&rft.au=Andrews,%20L&rft.date=2015-12&rft.volume=34&rft.issue=12&rft.spage=1279&rft.epage=1285&rft.pages=1279-1285&rft.issn=0960-3271&rft.eissn=1477-0903&rft_id=info:doi/10.1177/0960327115603594&rft_dat=%3Csage_AFRWT%3E10.1177_0960327115603594%3C/sage_AFRWT%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/26614816&rft_sage_id=10.1177_0960327115603594&rfr_iscdi=true |